Format

Send to

Choose Destination
Pharmacotherapy. 2003 Dec;23(12):1558-63.

Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study.

Author information

1
Department of Pharmacy Practice, Albany College of Pharmacy Albany, New York 12208, USA. elwellr@acp.edu

Abstract

STUDY OBJECTIVE:

To assess the influence of various clinical factors on antibody production induced by hepatitis B vaccine in patients receiving hemodialysis up to 24 months after vaccination.

DESIGN:

Retrospective cohort study.

SETTING:

Outpatient dialysis center.

PATIENTS:

Adult patients undergoing hemodialysis who received a three-dose series of intramuscular hepatitis B vaccine 40 microg at time 0, 1, and 6 months, according to protocol.

MEASUREMENTS AND MAIN RESULTS:

Antibody to hepatitis B surface antigen (anti-HBs) titers were monitored quarterly, and booster doses were given according to protocol. Patients with anti-HBs of at least 10 mIU/ml were considered seropositive. Clinical variables--age, diabetes mellitus status, serum albumin level, and equilibrated Kt/V (eKt/V; Kt/V is a measure of urea clearance during dialysis, used to quantify the delivered dose of hemodialysis)--were compared between seropositive and seronegative patients 12 months (cohort 1) and 24 months (cohort 2) after vaccination. In cohort 1 (66 patients), 24 (36.4%) were seropositive at 12 months. In cohort 2 (40 patients), 15 (37.5%) were seropositive at 24 months. Comparison of seropositive and seronegative patients revealed no statistically significant differences in mean age, sex, serum albumin level, or eKt/V. However, at 24 months, patients with diabetes were 2.5 times more likely to demonstrate seropositivity than those without diabetes (60% vs 24%, respectively, p=0.02).

CONCLUSION:

Long-term seroprevalence induced by hepatitis B vaccine was low in our patients 12 and 24 months after vaccination. These results were comparable to previously reported long-term results. Larger, prospective studies would be needed to confirm the finding that patients with diabetes had superior hepatitis B vaccine-induced antibody production at 24 months.

PMID:
14695036
DOI:
10.1592/phco.23.15.1558.31954
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center